Pancreatic Cancer Research

ResearcherChina Medical UniversityActive in the last 2 years

Wen‐Hwa Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3117-931X; OpenAlex author ID A5061314864. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
15
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 8

  1. Exosomal miRNA 16-5p/29a-3p from pancreatic cancer induce adipose atrophy by inhibiting adipogenesis and promoting lipolysis. Co-author DOI 10.1016/j.isci.2024.110346↗
  2. Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41419-022-05259-w↗
  3. Characterization of initial key steps of IL-17 receptor B oncogenic signaling for targeted therapy of pancreatic cancer. Last author DOI 10.1126/scitranslmed.abc2823↗
  4. Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-07109-6↗
  5. Cellular 5-hydroxylmethylcytosine content determines tumorigenic potential and prognosis of pancreatic ductal adenocarcinoma. Last author PMID 30662811↗
  6. A High Circulating Tumor Cell Count in Portal Vein Predicts Liver Metastasis From Periampullary or Pancreatic Cancer: A High Portal Venous CTC Count Predicts L… Last author DOI 10.1097/md.0000000000003407↗
  7. Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1373/clinchem.2015.248260↗
  8. Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. Last author DOI 10.1084/jem.20141702↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chun‐Mei Hu · 4 shared papers, 2018–2024 · strength 0.64
  2. Yu‐Ting Chang · 6 shared papers, 2016–2024 · strength 0.63
  3. Ming‐Chu Chang · 6 shared papers, 2016–2024 · strength 0.63
  4. Hsuan‐Yu Peng · 2 shared papers, 2019–2024 · strength 0.34
  5. Yu‐Wen Tien · 5 shared papers, 2015–2021 · strength 0.33
  6. Yung‐Ming Jeng · 4 shared papers, 2015–2021 · strength 0.28
  7. Sui-Chih Tien · 1 shared paper, 2024 · strength 0.23
  8. Yu-Huei Liu · 1 shared paper, 2022 · strength 0.22
  9. Y.M. Chen · 2 shared papers, 2018–2021 · strength 0.18
  10. Heng‐Hsiung Wu · 2 shared papers, 2015–2021 · strength 0.16
  11. Chun-Mei Hu · 1 shared paper, 2019 · strength 0.11
  12. Lung‐Hung Tsai · 1 shared paper, 2021 · strength 0.11
  13. Chia‐Ning Shen · 1 shared paper, 2021 · strength 0.11
  14. Shih‐Hung Yang · 1 shared paper, 2016 · strength 0.05
  15. Mei‐Fang Cheng · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.